Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Journal of the Neurological Sciences|November 19, 2024
Multi-Omic characterization of the effects of Ocrelizumab in patients with relapsing-remitting multiple sclerosisSergey A Kornilov, Nathan D Price, Richard Gelinas, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
Persistent Classical and Atypical Memory B Cells Underlie Heterogeneous Vaccine Responses in Ocrelizumab-Treated Multiple SclerosisRyan Curtin, Yogambigai Velmurugu, Fatoumatta Dibba, et al.
Annals of Clinical and Translational Neurology|February 22, 2023
Safety and patient experience with at-home infusion of ocrelizumab for multiple sclerosisBritney Barrera, Haley Simpson, Eric Engebretson, et al.
Annals of Clinical and Translational Neurology|May 7, 2024
Longitudinal study of immunity to SARS-CoV2 in ocrelizumab-treated MS patients up to 2 years after COVID-19 vaccinationIlya Kister, Ryan Curtin, Amanda L Piquet, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 13, 2016
Tolerance checkpoint bypass permits emergence of pathogenic T cells to neuromyelitis optica autoantigen aquaporin-4Sharon A Sagan, Ryan C Winger, Andrés Cruz-Herranz, et al.
Annals of Clinical and Translational Neurology|September 27, 2022
Hybrid and vaccine-induced immunity against SAR-CoV-2 in MS patients on different disease-modifying therapiesIlya Kister, Ryan Curtin, Jinglan Pei, et al.
Annals of Neurology|March 15, 2022
Cellular and Humoral Immunity to SARS-CoV-2 Infection in Multiple Sclerosis Patients on Ocrelizumab and Other Disease-Modifying Therapies: A Multi-Ethnic Observational StudyIlya Kister, Yury Patskovsky, Ryan Curtin, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 12, 2023
Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activityKoji Shinoda, Rui Li, Ayman Rezk, et al.
JAMA Neurology|March 11, 2024
Emerging Cerebrospinal Fluid Biomarkers of Disease Activity and Progression in Multiple SclerosisAnne H Cross, Jeffrey M Gelfand, Simon Thebault, et al.
Pageof 2